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Antiplatelet Therapy in Peripheral Arterial Disease.
Consensus Statement
Peripheral Arterial Diseases Antiplatelet Consensus Group
Department of Vascular Surgery, Northern Vascular Centre, Freeman Hospital, Newcastle upon Tyne, U.K.
Objectives: Antiplatelet agents are commonly prescribed to reduce the risk of myocardial infarction, stroke and graft
occlusion in patients with peripheral arterial disease (PAD). The objective was to summarise current evidence and provide
recommendations on the use of antiplatelet agents in PAD.
Methods: A consensus group was assembled including 20 specialists from a variety of fields involved in the management of
patients with PAD. Data was circulated in a systematic manner prior to a main consensus meeting held in November 2001.
The document subsequently produced was circulated within the group to ensure agreement in the interpretation and
presentation of its findings.
Results: Consensus recommendations are provided in 7 common or contentious scenarios in PAD. The recommendations
are graded to reflect the evidence available and interpretations of the group. Although the document provides recommenda-
tions, it is stressed that they must be interpreted in the light of individual patient circumstances.
Conclusion: Antiplatelet agents have an important role in the management of patient with PAD. Although this document
provides consensus recommendations, the optimum treatment in many scenarios remains unclear due to a lack of focussed
clinical trials in PAD.
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Introduction
Peripheral arterial disease (PAD) is a major healthcare
problem and is associated with a significant increase
in the risk of myocardial infarction (MI) and stroke.1
Intermittent Claudication (IC) is the commonest mani-
festation of PAD and is present in approximately 4%
of those over 50 years.2,3 In itself IC is a relatively
benign condition with less than 5% of patients per
5 years deteriorating and requiring peripheral arterial
intervention.4,5 In the Systolic Hypertension in the
Elderly Program, the age adjusted relative risk of
death with an ankle brachial pressure index (ABPI)
50.9 was 3.0 in men and 2.67 in women.6 The results
were similar for cardiovascular mortality and per-
sisted even after adjustment for other cardiovascular
risk factors and are similar to findings in other
studies.7,8
Evidence from meta-analyses confirms that the
long-term use of antiplatelet agents reduces the rate
of MI and ischaemic stroke in patients with symptom-
atic PAD;9±11 however, there are many `` scenarios'' in
vascular surgery where this evidence is less strong
and with the emergence of newer agents, additional
questions arise relating to efficacy and cost. In add-
ition, strong evidence is not available on the effective-
ness of antiplatelet drugs in the perioperative period,
raising concerns as to whether the risk of bleeding
outweighs the benefits produced by inhibition of
thrombosis.
With the development of newer antiplatelet agents
and the constant generation of new evidence concern-
ing antiplatelet therapy, clinical decision-making can
be difficult. In order to summarise current data, and
consider contentious issues of management, a con-
sensus group was organised. The group aimed to
summarise current evidence concerning antiplatelet
agents in patients with PAD, and generate guidelines
for use in hospital and the community (Fig. 1). Specific
attention was given to providing clarity in contentious
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areas (Fig. 2). The document can also be used as a
reference for other health professionals managing
patients with PAD. In addition, controversy exists
over the management of patients with recurrent
vascular events and those intolerant of aspirin. The
consensus group was organised to address some of
these issues.
Methods
Organisation of the conference
The organisers of the conference used their experience
of previous similar conferences and also sought guid-
ance from the `` Heath Technology Assessment'' review
of `` Consensus development methods, and their use
in clinical guideline development''.12 The main con-
sensus meeting was held on the 2nd and 3rd of
November 2001.
Participants were selected from defined specialist
categories involved in the management of patients
with PAD and its associated disorders, including
specialists in trial design and epidemiology. The key
consensus questions were judged to be representative
of common clinical scenarios in PAD and identified at
an early stage in the process (Fig. 2). Review-based
evidence was provided prior to the consensus meeting
and participants were encouraged to bring further
data identified outside the review. During the meeting
information was presented in an open manner fol-
lowed by a structured assimilation of the findings,
giving all participants a chance to voice their opinion.
For each meeting session two facilitators from differ-
ing specialities were selected. The meeting timetable
provided scope to discuss matters arising, thus avoid-
ing the pressure to make decisions without carefully
considering the evidence.
Evidence considered
The literature considered for this document was iden-
tified from electronic databases and from references
cited in important publications. Data deemed suitable
to consider for the consensus process came from meta-
analyses, systematic reviews, randomised controlled
trials, and cohort and cross-sectional studies. When
appraising the evidence well conducted randomised
controlled trials and meta-analyses were most highly
ranked. Key references were available for consultation
during the meeting. In areas where there was insuffi-
cient data to produce evidence based recommenda-
tions, conclusions were drawn using the limited
scientific data that is available and the personal
expertise and experience of the participants. Evidence
was graded to reflect these deficiencies so as not to
mislead the reader. From the outset it was clear that
identifying areas where evidence is deficient and sug-
gesting where further research is required was an
important role of the meeting.
Grading of evidence and strength of recommendations
We elected to appraise evidence and grade strength
of recommendations using systems advocated by
Michaels et al.13 We would like to emphasise that the
letters and numbering used in these systems may
not directly relate to other evaluation systems in
operation. (Fig. 3).
Scenario 1
Antiplatelet agents in patients with intermittent
claudication (Fig. 4)
Evidence
There is considerable evidence that PAD is a marker
of coronary and cerebrovascular disorders, and that
patients with PAD should be considered as a `` high
risk group'' for stroke and MI.2,14,15 Studies have
demonstrated that approximately half the patients
• To provide medical practitioners from all fields with evidence based 
recommendations on the use of antiplatelet therapy in peripheral
arterial disease patients.
 is required.
• Where strong evidence does not exist or is awaited, to provide 
guidelines that are sensible, safe and effective.
• To identify areas where evidence is deficient and further research
Fig. 1. Aims of the consensus meeting.
1. Intermittent claudication (IC)
2. Critical limb ischaemia (CLI) 
3. Angioplasty / stenting in peripheral arteries
4. Peripheral bypass grafting 
5. Abdominal aortic aneurysm
6. Recurrent vascular events
7. Patients taking non-aspirin NSAIDs
Fig. 2. Clinical scenarios considered.
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with symptomatic PAD also have evidence of IHD,16
and have almost a twofold increase in mortality,
predominantly from ischaemic heart disease and
stroke.3,17,18 When examining the supportive evidence
for the use of antiplatelet drugs in patients with PAD
we have three main sources of evidence to consider;
firstly studies comparing agents to placebo, secondly
studies comparing one agent against another, and
Summary of evidence: 
• Peripheral arterial disease is a marker of generalised cardiovascular risk. (I) 
• Antiplatelet agents reduce cardiovascular events and death in patients with
intermittent claudication. (I) 
• Clopidogrel is more effective than aspirin in preventing vascular events
(overall 8.7% proportional reduction in risk). (I) 
• Aspirin 75-325 mg daily seems effective (I), and has lower side effects than an
aspirin dose >325 mg. (II)
Recommendations: 
• All patients with intermittent claudication or who have had previous vascular
intervention should be considered for long-term anti-platelet therapy. (A) 
• The agents used should be either Aspirin 75-325 mg daily (A) or Clopidogrel
75 mg per day. (A) 
Fig. 4. Scenario 1: Antiplatelet agents in patients with intermittent claudication.
Grading of Evidence
Grade I. “Beyond reasonable doubt”
Evidence from high quality randomized controlled trials, systematic reviews, or
large observational data-sets which is directly applicable to the specific population 
of concern and has clear results. 
Grade II. “On the balance of probabilities”
Evidence of  ‘best practice’ from a high quality review of the literature, which 
fails to reach the highest standard of proof due to heterogeneity, questionable trial 
methodology or lack of evidence in the population to which the guidelines apply.
Grade III. “Unproven”
Contradictory evidence or insufficient evidence upon which to base a decision.
Strength of recommendations
A. A strong recommendation, which should be followed unless there are 
compelling reasons not to do so. 
B. Recommendation based on evidence of effectiveness that may need
interpretation in the light of other factors (e.g. patient preferences, local facilities, 
local audit results or available resources)
C. Recommendations where there is inadequate evidence on effectiveness but
pragmatic or financial reasons to institute an agreed policy.
Fig. 3. Grading of evidence and strength of recommendations.
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thirdly extrapolation of data from trials in IHD and
CVD. Over the last 10 years it has become accepted
that antiplatelet drugs are effective in reducing cardio-
vascular mortality and morbidity in patients with vas-
cular disease, and consequently placebo controlled
studies have become effectively unethical. Current
studies now focus on comparing new agents against
existing treatment, such as aspirin.
Antiplatelet vs placebo studies in PAD (Table 19,19±31)
In IHD and CVD there is now little disagreement that
patients benefit from antiplatelet therapy, with aspirin
being first choice for general prophylaxis.32,33 Consid-
ering all antiplatelet drugs together there is now
strong evidence confirming the benefits of antiplatelet
agents in reducing MI, stroke and vascular death in
patients with symptomatic PAD, as confirmed by the
ATTC34 and the systematic review by Robless et al.9
Both studies demonstrated an approximate 25%
reduction in all vascular events. Although in antipla-
telet studies of patients with IHD and CVD a large
proportion of data for meta-analyses comes from trials
of aspirin, in PAD the actual number of suitable trials
of aspirin versus placebo is small. Therefore, the
results of meta-analyses of antiplatelet agents in PAD
are much more dependent on drug trials involving
picotamide and the thienopyridines. There have been
no randomised, blinded, placebo controlled trials of
dipyridamole alone in the prevention of vascular
events. Picotamide has been demonstrated to be an
effective antiplatelet agent compared with placebo,
but no clinical trials have shown it to be more effective
than current antiplatelet agents. Despite increasing
walking distance, Cilostazol has not been demon-
strated to be more effective than placebo in reducing
MI in claudicants.35
Comparison of one antiplatelet against another in PAD
In the five trials of one antiplatelet regime against
aspirin there appeared to be a benefit for the second
agents with the biggest effect shown in the CAPRIE
study. Overall in CAPRIE there was a relative risk
reduction in outcome events of 8.7% (CI 0.3±16.5;
p 0.043) in favour of clopidogrel over aspirin. In the
PAD subgroup the relative risk reduction was greater
at 23.8% (CI 8.9±36.2; p 0.0028)36 (Table 223,36±40).
Risk of bleeding complications with long term use of
antiplatelet agents
Aspirin is the most widely used antiplatelet agent and
data from the ATTC suggests that doses less than
325 mg are equally as effective as higher doses.34 It
has been established that there is a small but signifi-
cant increase in bleeding complications with long-
term aspirin use, and the trend has been towards
prescribing lower doses of aspirin. Despite this ten-
dency, and the conflicting results of individual trials
comparing aspirin doses, a large meta-analysis was
unable to demonstrate a significant reduction in bleed-
ing complications with these lower doses of aspirin.41±43
The study also concluded that aspirin therapy should
only be instituted if the risk of vascular events 41.5%
per year for benefit to outweigh risk.43
Most of the data on the relative safety of clopidogrel
comes from the `` Clopidogrel vs Aspirin in Patients at
risk of Recurrent Ischaemic Events study'' (CAPRIE),
comparing aspirin 325 mg OD with clopidogrel 75 mg
OD.36 In this study the frequency of GI haemorrhage
and upper GI symptoms were significantly lower in
patients on clopidogrel than those on aspirin. A study
in cardiac disease has shown that when aspirin is
combined with clopidogrel the relative risk of major
bleeding was increased 1.38 (CI 1.13±1.67); however
there was no statistically significant excess in fatal
bleeding or bleeding requiring surgical intervention.44
There is no clear evidence that dipyridamole alone
increases bleeding, although headache, its commonest
side effect may require drug withdrawal. In the Eur-
opean Stroke Prevention Study 2 (ESPS-2), dipyrida-
mole alone showed no increase in rates of adverse
bleeding when compared with placebo; however,
patients treated with aspirin alone or aspirin plus
dipyridamole had higher rates of adverse bleeding
than the placebo treated group.45
Table 1. Placebo controlled studies in stable claudicants assessing
vascular events.9
Antiplatelet Drug Numbers of
patients
Aspirin19 258
Aspirin plus Dipyriamole20±23 471
Ticlopidine24±26,28±30 1990
Picotamide31 2304
Studies with vascular events as part of the primary endpoints.
Table 2. Studies comparing different antiplatelet regimes in PAD.
Study Antiplatelet agents compared Numbers of
patients
CAPRIE 199636 Clopidogrel vs Aspirin 6452 (with IC)
Hess 198523 Aspirin vs Aspirin plus
Dipyridamole
240
Libretti 198637 Aspirin vs Aspirin plus
Dipyridamole
54
Schoop 198338,39 Aspirin vs Aspirin plus
Dipyridamole
300
Schoop 198340 Aspirin vs Ticlopidine 62
CAPRIE was the only PAD study to assess vascular events in its
outcome measures.
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Recommendations
Patients with a diagnosis of symptomatic PAD,
preferably confirmed by an ABPI 50.90, should
receive antiplatelet therapy. This includes asymp-
tomatic patients who have previously undergone
intervention for symptomatic disease. The 2002
ATTC demonstrated that aspirin at doses of 75±
150 mg appears to be at least as effective as
aspirin at higher doses in high-risk patients.34 There
is little information on the value of antiplatelet
agents in those patients with an ABPI50.9 who are
asymptomatic; however, they are at high risk of vas-
cular events. When dipyridamole is prescribed, it is
recommended that it is given in combination with
aspirin.
There is evidence that the thienopyridines
(clopidogrel and ticlopidine) are more effective than
aspirin alone. In direct comparisons with aspirin,
there was an odds reduction in vascular events of
10% favouring clopidogrel, and 12% favouring ticlo-
pidine. Furthermore, if one combines the indirect
comparisons using 43 trials of ticlopidine against con-
trol (32% odds reduction) and the 65 trials of aspirin
against control (23% odds reduction), the derived
odds reduction for ticlopidine versus aspirin is
10.5%. This is entirely consistent with the estimate
from direct comparisons and strengthens the evidence
of superiority of the thienopyridines over aspirin.
While clopidogrel and ticlopidine appear equally effi-
cacious, the safety profile of clopidogrel is markedly
better and one can no longer justify the use of ticlopi-
dine. However, aspirin is the agreed first line treat-
ment for secondary prevention in IHD in the U.K. as it
is both effective and cheap.32,33 With these cost-benefit
issues the choice between aspirin and clopidogrel is
likely to remain contentious until further data
emerges.
Scenario 2
Antiplatelet agents in patients with critical limb
ischaemia (CLI) (Fig. 5)
Evidence
There are no published trials showing that oral anti-
platelet drugs improve limb salvage in patients with
CLI. Patients with CLI are at high risk of MI and
stroke, therefore providing a justification for antipla-
telet prophylaxis. Whenever possible CLI should be
managed with surgical or endovascular intervention
and these scenarios are covered in the appropriate
sections of this document, as are the risks of bleeding
associated with the use of antiplatelet agents.
Recommendation
As with patients with IC, those with CLI should
be treated with antiplatelet therapy for reduction of
cardiovascular risk, with the choice being between
aspirin and clopidogrel.
Scenario 3
Antiplatelet therapy in angioplasty and stenting in
peripheral arteries (Fig. 6)
Evidence
In patients undergoing peripheral arterial angioplasty
and stenting, issues arise regarding the risk and bene-
fit of antiplatelet therapy. Antiplatelet therapy can
reduce arterial thrombosis in the target vessel, coron-
ary and cerebrovascular circulation, but carries the
risk of increasing bleeding complications.
Summary of evidence:
• Patients with critical limb ischaemia are at high risk of subsequent
cardiovascular events especially MI and stroke. (II)
• There is no compelling published data that antiplatelet agents alter the 
outcome for the limb in patients with critical limb ischaemia. (II)
Recommendations: 
• All patients with critical limb ischaemia, or who have had previous vascular
intervention should be considered for long-term anti-platelet therapy (A) 
• The agents used should be either Aspirin 75-325 mg daily (A) or Clopidogrel
75 mg per day (A) 
Fig. 5. Scenario 2: Antiplatelet agents in patients with critical limb ischaemia.
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Reduction in cardiovascular events. In comparison with
operative surgery the cardiovascular mortality is lower
in patients undergoing peripheral angioplasty.46,47
There is no good data demonstrating that antiplatelet
drugs reduce periprocedure cardiovascular events.
Target vessel occlusion. A systematic review by Watson
et al.48 of antiplatelet agents in peripheral angioplasty
and stenting was unable to demonstrate that anti-
platelet drugs reduce the rate of target vessel re-
occlusion. The review was limited by the scarcity of
good quality trials of antiplatelet drugs in patients
undergoing peripheral angioplasty. In coronary angio-
plasty and stenting large trials have demonstrated the
benefits of antiplatelet agents, and also that different
agents can act synergistically.44,49,50 For patients not
on an antiplatelet treatment it is suggested that a
300 mg dose of aspirin should be given at least 2 h
prior to the procedure. If lower doses are used poten-
tial delays in bio-availability may occur.49
The 1994 ATTC demonstrated that when arterial
disease is taken together as a whole, occlusion is
significantly reduced by 44% with the use of antipla-
telet therapy, while treatment continues (p 0.00001);
however, when peripheral angioplasty is analysed
separately a 47% non-significant reduction in occlu-
sion is seen.51
Although there have been promising results in ani-
mal studies52,53 suggesting that antiplatelet agents
reduce neo-intimal hyperplasia there is no consistent
evidence that conventional antiplatelet agents reduce
restenosis. Several human studies of coronary artery
intervention have suggested that cilostazol may
reduce the restenotic process, however, these data
are not supported in peripheral arterial interven-
tion.54,55 There is currently no evidence to support
the use of other antiplatelet agents in preventing rest-
enosis after angioplasty and stenting.
Bleeding complications. We were unable to identify any
large prospective, placebo-controlled studies in per-
ipheral angioplasty providing detailed information
on local or systemic bleeding complications associated
with the use of antiplatelet therapy.
The 1994 ATTC51 demonstrated that when antipla-
telet drugs were started prior to vascular intervention
there was a small but significant increase in major
bleeds (13 4 per 1000) and the need for re-operation
for major bleeding. These data are not specific for
peripheral angioplasty and do not consider the
adverse vascular events prevented by treatment.
Patients undergoing percutaneous coronary inter-
vention in the CURE study were found to have a
statistically significant increase in minor bleeding
during their longer-term follow-up (CI 1.68(1.06±2.68)
p 0.03), although not within 30 days of the proced-
ure.56 A statistically significant increase in major
bleeding or transfusion requirements was not found
with the addition of clopidogrel to aspirin during the
study in the PCI-CURE sub-study patients.
Summary of evidence: 
• Patients undergoing vascular radiological intervention are at high risk of
subsequent MI and stroke. (I)
• Continuing antiplatelet agents around the time of vascular intervention may 
reduce the risk of periprocedure MI. (III)
• There is limited evidence, extrapolated from cardiac angioplasty and stenting 
that antiplatelet agents increase bleeding complications from percutaneous
arterial puncture sites. (III)
• There is limited evidence that antiplatelet agents reduce restenosis. (III)
Recommendations: 
• All patients with symptomatic peripheral arterial disease or who have had 
previous vascular intervention should be considered for long-term anti-platelet 
therapy, unless contraindicated (A)
• Aspirin should be continued peri-procedure unless a particular concern over 
increased bleeding exists. (B)
• Consideration should be made to stopping clopidogrel 5 days prior to elective
surgery. (C) 
Fig. 6. Scenario 3: Antiplatelet therapy in angioplasty and stenting in peripheral arteries.
6 Peripheral Arterial Diseases Antiplatelet Consensus Group
Eur J Vasc Endovasc Surg Vol 26, July 2003
Recommendations
There seems to be no strong evidence to support the
stopping of aspirin prior to angioplasty and stenting
in patients with PAD. In addition it is recommended
that patients not on aspirin, and who are candidates
for antiplatelet prophylaxis should receive a loading
dose of aspirin (300 mg) at least 2 h prior to the
procedure. With clopidogrel, the safest option may
be to start the drug immediately following the proced-
ure. When patients are already on clopidogrel con-
sideration should be made to stopping it 5±7 days
prior to the procedure if bleeding risks are thought
to be high.
Scenario 4
Antiplatelet therapy in peripheral arterial bypass
surgery. (Fig. 7)
Evidence
As with peripheral angioplasty, the risk and benefit of
antiplatelet therapy require careful evaluation in
patients undergoing peripheral bypass surgery. In
the case of surgery, the risk of cardiovascular events
is higher in the perioperative period and more evi-
dence is available on a wider range of antithrombotic
agents than with angioplasty.
Reduction of cardiovascular events. In the meta-analysis
by Robless et al., which looked at all vascular events in
PAD patients, a non-significant reduction in vascular
events was observed (relative risk 0.76, 95% CI 0.54±
1.05) in patients undergoing lower limb bypass asso-
ciated with antiplatelet therapy.9 This may reflect a
type 2 statistical error due to a lack of includable trials.
Improvement of patency. The 1994 ATTC demonstrated
that vascular occlusion was significantly reduced by
around 40% with antiplatelet therapy in patients
undergoing coronary and peripheral arterial bypass
surgery while treatment continues (p 0.00001). Ele-
ven of these trials (42000 patients) involved patients
undergoing peripheral bypass surgery and the analy-
sis demonstrated a significant reduction in graft occlu-
sion (38% odds reduction).11 In a more recent
systematic review of antiplatelet agent versus placebo
in infrainguinal bypass, only five trials were found to
be suitable for inclusion.57 The review demonstrated a
significant reduction in occlusion rates with antiplate-
let agents, (risk reduction 0.78, 95% CI 0.64±0.95).
A similar review by Girolami also demonstrated a
significant benefit from antiplatelet drugs in prevent-
ing peripheral bypass graft occlusion.58 Following the
data cut off date for Tangelder's systematic review, the
result of a large placebo controlled trial (243 patients)
of ticlopidine in patients undergoing infrainguinal
Summary in evidence:
• Patients undergoing vascular surgical intervention are at an additional high risk
of subsequent MI and stroke. (I)
• Continuing antiplatelet agents around the time of surgery may increase the risk
of haemorrhagic complications. (II)
• Continuing antiplatelet agents around the time of vascular intervention may 
reduce the risk of perioperative MI. (II)
• Evidence suggests that either antiplatelet agents or anticoagulation improve the 
long-term patency of vascular grafts. (II)
Recommendations: 
• All patients with symptomatic peripheral arterial disease or who have had 
previous vascular intervention should be considered for long-term anti-platelet 
therapy, unless contraindicated (A)
• Aspirin should be continued peri-procedure unless a particular concern over 
increased bleeding exists. (B)
• Consideration should be made to stopping clopidogrel 5 days prior to elective
surgery. (B) 
Fig. 7. Scenario 4: Antiplatelet therapy in peripheral bypass surgery.
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saphenous vein bypass grafts has been published.25
This demonstrated a significant improvement in
long-term graft patency with ticlopidine. When the
agents used are considered individually there is
data related to aspirin plus dipyridamole, ticlopidine
and warfarin25,59±64 (Table 3).
Aspirin
Five randomised, double blind placebo controlled stu-
dies of aspirin plus dipyridamole have been reported.
Meta-analysis of this data has shown a statistically
significant reduction in graft occlusions with aspirin
plus dipyridamole (relative risk 0.78 (0.64±0.95)).57
Interestingly, the largest and longest duration study
showed no statistically significant effect of antiplatelet
drugs on graft occlusion. It is plausible that the anti-
platelet effect is most important for short and medium
term patency, and as time progresses, progression of
the underlying disease contributes more to graft fail-
ure. It is also of note that the studies by Green and
Donaldson, which both had highly significant results,
only included prosthetic grafts (Table 3).
Ticlopidine
The study by Becquemen 1997 is the only blinded
placebo controlled study of ticlopidine in peripheral
bypass.25 The study assesses saphenous vein graft
patency, death and vascular events in 243 patients
undergoing infrainguinal bypass. Graft patency was
significantly improved in the ticlopidine treated
patients at two years (66.4 vs 51.2%, p 0.02),
although there was no statistically significant reduc-
tion in death or ischaemic events.
Anticoagulation
Only one long-term placebo controlled study has been
published assessing the effect of anticoagulation alone
in peripheral bypass graft patency. The aim of the
study was to determine whether long-term oral anti-
coagulant treatment was effective in improving graft
performance and preventing major amputation
following femoropopliteal autologous vein bypass
for atherosclerosis. The trial involved a single center
and continued for over 10 years. The study demon-
strated that anticoagulation was superior in terms of
graft patency, limb salvage, and survival (Table 3).
A controlled study showed no significant reduction
in graft patency rates with oral anticoagulation during
the 5-year follow up;65 however, the study included in
its randomisation patients with thromboendartectomy,
central reconstruction and conservative treatment.
Antiplatelet agent versus anticoagulation
The Dutch Bypass or Oral anticoagulants or Aspirin
study (BOA) was designed to investigate which of
these possible treatments proved most effective fol-
lowing infrainguinal bypass.66 Analysis of the data
demonstrated no overall difference between the two
treatments; however, when the subgroups of pros-
thetic and autologous vein graft were analysed,
prophylaxis with oral anticoagulation favoured auto-
logous vein graft patency (0.69; 95% CI 0.54, 0.88) and
aspirin favoured prosthetic graft patency (1.26; 95% CI
1.03, 1.55). It is worth noting that a positive value
favours oral anticoagulation and negative favours
aspirin. Patients treated with oral anticoagulation in
this study had an excess of major bleeds in compari-
son with aspirin treatment (Hazard ratio 1.96, 95% CI
1.42±2.71). One small study from Sarac (n 56)
demonstrated a significant reduction in graft occlu-
sions with the combination of aspirin plus oral anti-
coagulant versus aspirin alone in patients with grafts
at high risk of failure (3-year cumulative patency 74%
vs 51%, p 0.04). The incidence of postoperative
Table 3. Studies assessing the effect of antiplatelet agent on peripheral graft patency.
Study author Year Active treatment
(number pts)
Placebo
(number pts)
Follow up
(months)
Graft patency
relative risk (95% CI)
Aspirin
Green59 1982 16 & 16  17 12 0.35 (0.18±0.69)
Goldman60 1984 22 31 12 0.52 (0.26±1.02)
Kohler61 1984 50 50 24 1.25 (0.85±2.39)
Donaldson62 1985 33 32 12 0.26 (0.10±0.70)
McCollum63 1991 286 263 36 0.92 (0.72±1.18)
Ticlopidine
Becquemin25 1997 122 121 1997 0.77 (0.73±0.97)
Warfarin
Kretschmer y64 1992 66 64 120 0.55 (0.33±0.99)
Randomised, double-blinded, placebo controlled studies, 12 months duration.Aspirin plus dipyridamole.
yNot blinded or placebo controlled.
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haematoma was greater in the aspirin plus warfarin
group (32% vs 3.7%, p 0.004). Because of this limited
data, on aspirin and warfarin, and the potential
increased risk of bleeding complications, we cannot
advocate this combination routinely.67
The overriding problem faced when reviewing this
data is that studies to date have involved differing
combinations of antithrombotic agents and bypass
materials, making individual comparison of results
difficult. Both antiplatelet therapy and oral anticoagu-
lation are effective measures to maintain patency in
infrainguinal grafts.51,57,58 Previously there has been a
tendency in clinical practice to opt for anticoagulation
in `` high risk'' grafts, such as prosthetic and pedal
bypasses and aspirin in the rest.
Current data would suggest that antiplatelet agents
are slightly more effective than anticoagulation in the
prevention of prosthetic bypasses occlusion, and anti-
coagulation is slightly more effective for vein graft
occlusion; however, anticoagulation increases the
haemorrhagic risk and poses other management issues.
Vein graft thrombotic prophylaxis must therefore
remain an area for local or individual decision (Fig. 8).
Risk of perioperative bleeding. In vascular surgery there
are very few studies that have satisfactorily assessed
the effect of antiplatelet agents on bleeding complica-
tions as part of their primary study design.63 In a large
multi-centre trial of aspirin plus dipyridamole versus
placebo, 549 patients underwent saphenous vein
femoropopliteal bypass.63 No difference in patency
rates was demonstrated between the groups, although
a significant reduction (p 0.004) in MI and stroke
was observed in patients randomised to the anti-
platelet drugs. However, the rate of re-operation for
bleeding was almost double in the aspirin plus dipyri-
damole group, although this did not reach statistical
significance (p 0.13). Likewise there was no differ-
ence in the incidence of wound haematomas or GI
bleeding.
Controversy remains as to whether patients should
stop antiplatelet therapy prior to vascular interven-
tion. There is some evidence that periprocedural
antiplatelet therapy may reduce the rate of acute
re-occlusion, although this may increase the risk of
bleeding. Studies in coronary artery bypass have
shown that the perioperative timing of antiplatelet
agents is important and that antiplatelet agents can
reduce mortality in patients undergoing coronary
artery bypass grafting (CABG). In a large case control
study of 8641 consecutive patients undergoing CABG,
the odds ratio for a reduction of in-hospital mor-
tality with preoperative aspirin therapy was 0.73
(p 0.03).68 No significant difference was seen in the
quantity of chest tube drainage, transfusion require-
ment or need for re-exploration due to haemorrhage.
In line with the manufacturers recommendations
and the findings of several studies of thienopyridines
in cardiac surgery, caution must be exercised in the
perioperative use of these drugs. Patients participat-
ing in the CURE study who underwent coronary
artery bypass grafting had an increased risk of major
bleeding if clopidogrel was taken during the 5 days
preceding surgery.44 There is likely to be an increased
risk of haemorrhage associated with clopidogrel dur-
ing open peripheral arterial surgery.69
Recommendations
In patients with PAD aspirin should be continued
peri-procedure unless particular concerns exist over
operative bleeding in patients undergoing surgical
peripheral arterial intervention. Clopidogrel may
increase operative bleeding and consideration should
be made to stopping it 5 days prior to surgery. In
addition to their long-term benefits in reducing rates
of MI and stroke, antiplatelet agents are recom-
mended to maintain infrainguinal graft patency. As
an alternative to antiplatelet agent therapy, oral anti-
coagulation is an acceptable in the case of autologous
• Meta-analysis has demonstrated that overall antiplatelet agents can help prevent 
graft occlusion following infrainguinal bypass surgery.
• Aspirin appears more effective than anticoagulation in preventing prosthetic
graft occlusion.
• Anticoagulation appears more effective than aspirin in preventing autologous
vein graft occlusion.
• Ticlopidine is more effective than placebo in preventing vein graft occlusions. 
Fig. 8. Antithrombotic drugs in maintaining infrainguinal bypass patency.
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vein bypass and other grafts deemed at high-risk of
failure (Fig. 8).
Scenario 5
Antiplatelet agents in patients with aortic
aneurysms (Fig. 9)
Evidence
Although there is evidence that platelet accumulation
is reduced in patients with aortic aneurysms taking
aspirin there is no evidence that antiplatelet drugs
reduce clinically important peripheral embolic events
or aneurysm growth.70 Data from the `` U.K. Small
Aneurysm Trial'' demonstrated that patients with
aortic aneurysms and a reduced ABPI have a particu-
larly high mortality for cardiovascular death (66% of
deaths).71 These data also suggest that antiplatelet
therapy with aspirin should be considered as the year-
ly risk of cardiovascular events was greater than 1.5%,
such that the benefit outweighs the risk of bleeding.43
In support of the presence of an AAA being a marker
of vascular risk, the National Cholesterol Education
Program (NCEP), Adult Treatment Panel (ATP) ± III
guidelines, now consider the presence of an abdom-
inal aortic aneurysm to be a coronary heart disease
(CHD) risk equivalent ( 20% cardiac events rate in
10 years).72
Recommendation
It is recommended that all patients with an
abdominal aortic aneurysm and evidence of symp-
tomatic PAD should receive antiplatelet prophy-
laxis. Patients with an aortic aneurysm, but
without evidence of symptomatic PAD also have
a high risk of cardiovascular events, and therefore
should also be strongly considered for antiplatelet
prophylaxis.
Scenario 6
Antiplatelet agents in patients with recurrent
vascular events (Fig. 10)
Evidence
Information on the prevention of recurrent events in
PAD patients is scarce, and we need to extrapolate
from studies in IHD and CVD.
Possible causes of recurrent vascular events despite
antiplatelet therapy
Drug non-compliance. Routine toxicology tests are not
sensitive enough to measure therapeutic aspirin
levels. In addition, aspirin has a short half-life of
about 30 min and an antiplatelet effect can be detected
for about 7 days after the drug has been eliminated,
but clinically effective platelet inhibition may be lost
sooner. Non-compliance is likely to be a significant
factor in failure of antiplatelet therapy.
Aspirin resistance. It has been demonstrated that up to
25% of individuals have a reduced response to aspirin,
when measured by platelet aggregation tests.73,74
Although there is evidence that increasing the dose
of aspirin may partly counteract this aspirin resist-
ance, there is no evidence to support that increasing
the dose in these individuals improves clinical out-
come. A recent study evaluated urinary thromboxane
concentration as an indirect marker of aspirin effect.
The study demonstrated that those patients with high-
est urinary thromboxane concentrations had a signifi-
cantly greater risk of cardiovascular death.75
• The presence of an abdominal aortic aneurysm is a marker of generalised 
atherosclerosis and increased mortality from vascular disease. (II) 
• Patients with aortic aneurysms and low ABPI’s are those at highest risk of
adverse cardiovascular events. (II)
• Patients with abdominal aortic aneurysms and occlusive PAD should receive 
antiplatelet prophylaxis. (A)
• Those patients with aortic aneurysms without evidence of PAD should be
strongly considered for antiplatelet prophylaxis due to their high risk of future
vascular events. (B) 
Summary of evidence:
Recommendations: 
Fig. 9. Antiplatelet agents in patients with aortic aneurysms.
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Disease progression. No clear evidence exists on the
effects of antiplatelet therapy on disease progression.
Possible actions for patients with recurrent
vascular events are
 Continue current antiplatelet therapy (same dose).
 Increase dose (aspirin only), e.g., from 75 to 150 or
300 mg.74
 Change antiplatelet drug (e.g., aspirin ! clopido-
grel).76
 Add another antiplatelet agent42,44 e.g., aspirin plus
clopidogrel or dipyridamole.
 Change to oral anticoagulant. This option should be
considered particularly in the case of autologous
vein bypasses.66
Recommendation
The management of patients with recurrent vascular
events represents a contentious issue particularly
when identifying high-risk patients is often less than
clear. Each of the above regimes may be justified based
on current evidence (or lack of it). However, in the
absence of good clinical trial evidence it is difficult to
make recommendations, on comparative efficacy.
Scenario 7
Non-aspirin non-steroidal anti-inflammatory drugs
(NANSAIDs), Renal and GI toxicity in patients
with PAD (Fig. 11)
NANSAIDs and antiplatelet therapy in patients with
PAD. Concomitant administration of NANSAIDs
may be needed for the treatment of musculoskeletal
disorders in patients receiving antiplatelet prophy-
laxis with aspirin. In these circumstances concern
is often raised over the potential for GI and renal
toxicity, in addition patients with PAD are more likely
to be elderly and have renal vascular disease as part of
a more generalised atherosclerotic process, and are
hence at high risk of NANSAID induced renal toxicity.
COX-2 inhibitors (selective NANSAIDs) have a lower
risk of GI complications, but they have a similar
propensity to cause renal toxicity as conventional
non-selective NANSAIDs77,78 and they may also be
hazardous due to increases in blood pressure. There-
fore if at all possible the NANSAIDs should be stopped
in patients receiving aspirin as antiplatelet prophy-
laxis. In addition, there is currently no compelling
data that either selective or non-selective NANSAIDs
provide adequate antiplatelet effect for the pre-
vention of MI and stroke.79±82 All patients with
symptomatic PAD taking a NANSAID should there-
fore also receive an effective antiplatelet drug,
although with the caution that the combination of
aspirin plus NSAIDs may increase the risk of GI
bleeding.83
In two large randomised controlled trials of COX-2
inhibitors, the celecoxib long-term arthritis safety
study (CLASS) was unable to demonstrate a reduction
in ulcer complications in patients treated with cele-
coxib over patients treated with non-specific NSAIDs;
in the Vioxx (rofecoxib) gastrointestinal outcomes
research (VIGOR) study, GI complications were
lower with rofecoxib than with naproxen, although,
cardiovascular mortality was significantly increased.
Summary of evidence:
• Data from cardiac disease suggests that the combination of aspirin plus
clopidogrel is more effective than aspirin alone. (II)
• Data from cerebrovascular disease suggests that the combination aspirin plus
dipyridamole is more effective than aspirin alone. (II)
• In patients with autologous venous bypass grafts, oral anticoagulant may be
more effective than antiplatelet agents. (III)
• The evidence to support increasing the aspirin dose is limited. (III) 
Recommendations:
In patients with recurrent vascular events despite antiplatelet therapy, the 
following may be considered:
• Add in another antiplatelet agent (B)
• Change antiplatelet drug (eg: aspirin to clopidogrel) (C)
• Change to anticoagulant (C) 
Fig. 10. Antiplatelet agents in patients with recurrent vascular events.
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Subsequent analysis of the data from VIGOR with
other phase IIb and III trials of rofecoxib have sug-
gested that this increase in mortality relates more to
naproxen's antiplatelet activity rather than an increase
in cardiovascular events of rofecoxib.84 Differences in
trial design and comparative drugs make direct com-
parison between CLASS and VIGOR difficult.85,86
Guidance from U.K.'s National Institute of Clinical
Excellence (NICE) on the use of COX-2 inhibitors
suggests that they are used in preference over conven-
tional NSAIDs, in patients at high risk of GI complica-
tion including those over 65 years. They also state that
`` in patients taking low dose aspirin, the benefit of
using COX-2 selective agent (to reduce GI toxicity) is
reduced''. Prescribing COX-2 selective agents prefer-
entially over standard NSAIDs in this situation is
therefore not justified on current evidence.87
GI intolerance of NSAIDs
Patients with PAD, are likely to have at least one of the
risk factors for cyclo-oxygenase inhibitor induced GI
complications.88 To date there have been no rando-
mised trials on the effect of acid suppression on
cyclo-oxygenase inhibitor associated complications,
although studies have shown that proton pump inhi-
bitors (PPI) are protective, and long term studies have
shown them to prevent gastric and duodenal ulcers.
There may also be benefits in screening for and treat-
ing Helicobacter pylori infections in patients receiving
long term NANSAIDs.89,90
Not all conventional NSAIDs appear to have the
same risk of GI toxicity. A meta-analysis by Henry
et al.91 evaluated the variable risk of GI complications
with individual NSAIDs. The meta-analysis demon-
strated that ibuprofen had the lowest risk of GI com-
plications. Although this study does not examine the
comparative risk of each drug when combined with
aspirin, it is still a useful base to select a low risk
NSAID. However, new work suggests that some
COX-2 inhibitors may reduce the antiplatelet effect of
aspirin.92 In this study, the concomitant administra-
tion of ibuprofen but not rofecoxib, acetaminophen or
Summary of evidence: 
• Non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) can be
hazardous in patients with peripheral arterial disease and renal impairment, due
to renal toxicity. (II)
• COX-2 inhibitors may also be hazardous in patients with peripheral arterial
disease due to renal toxicity (II).
• There is no convincing evidence to date that conventional or selective (COX-2) 
NANSAIDs provide satisfactory cardiovascular protection. (II) 
• There is evidence that the combination of aspirin + NANSAIDs over aspirin 
alone increases the risk of gastrointestinal bleeding (II)
Recommendation:
• Patients with peripheral arterial disease, taking aspirin, should avoid 
NANSAIDs (including COX-2 inhibitors) if possible, particularly if they have a 
history of renal impairment. (B) 
• Patients with peripheral arterial disease who require both a NANSAID inhibitor 
plus an antiplatelet drug should consider either taking aspirin and a 
gastroprotective drug e.g. a proton pump inhibitor (B), or consider changing 
aspirin for clopidogrel as antiplatelet therapy. (C) 
• The following alternatives should be considered in a patient intolerant of aspirin 
for gastric reasons (following exclusion of other cause of ulceration): 
Stop any concomitant NANSAIDs , if possible. (B) 
Use clopidogrel instead of aspirin. (B) 
Add a proton pump inhibitor to aspirin for gastric protection. (B) 
Fig. 11. Antiplatelet agents, non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs), Renal and GI toxicity in patients with PAD.
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diclofenac antagonised the irreversible platelet inhib-
ition induced by aspirin.
As an alternative to prescribing aspirin plus a gas-
troprotective drug in patients with aspirin induced GI
toxicity, or as an alternative to the concomitant pre-
scription of aspirin plus NANSAID, clopidogrel may
be substituted for aspirin. Data from the CAPRIE
study, demonstrated that clopidogrel had a lower
risk for GI bleeding complications than aspirin; in
addition, clopidogrel has been shown to be associated
with less gastric irritation than aspirin.93 Clopidogrel
may be a preferred alternative to aspirin in patients
taking NANSAIDs, but no trial evidence supports this
option. Both changing the antiplatelet agent and the
co-prescription of a gastroprotective drug have cost as
well as clinical implications.
Cost Issues
The principle objective of this consensus was to assess
the evidence for antiplatelet drug efficacy in clinical
practice rather than to perform a cost analysis.
Although we appreciate that drug cost is a highly
important aspect to the effective delivery of limited
health care provisions, the resources required to
accurately identify the total `` costs'' of drugs was
beyond the scope of this consensus group in terms of
time, skills and funding. Overall, long-term antiplate-
let therapy appears a cost-effective strategy for the
prevention of MI, stroke and arterial re-occlusion
following therapeutic interventions in patients with
symptomatic PAD.34 Insufficient data exists on the
absolute costs of aspirin in comparison with alterna-
tive antiplatelet drugs, particularly when the adverse
events are taken into account. In a meta-analysis by
Hankey76 it was estimated that by substituting clopi-
dogrel for aspirin among high-risk patients, between
two and 19 patients may be prevented from having
one or more recurrent vascular events per 1000
patients treated; however, aspirin is cheap while alter-
natives are more costly. We recommend further stu-
dies of cost-effectiveness of different antiplatelet
therapies/combinations in PAD patients.
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